Institute of Virology, University of Cologne, Germany
Broadly neutralizing antibodies (bNAbs) targeting HIV-1 can prevent infection in animal models and are under investigation for passive immunization in clinical trials. Moreover, bNAbs have been demonstrated to suppress viremia in HIV-1-infected individuals. While these results highlight the significant clinical potential of bNAbs, pre-existing and de novo HIV-1 resistance causes treatment failure and limits bNAb applications in humans. Strategies to overcome viral escape and to enhance the efficacy of bNAbs are therefore critical.
The International Society for Antiviral Research (ISAR) is an internationally recognized organization for scientists involved in basic, applied, and clinical aspects of antiviral research. The Society main event is the annual International Conference on Antiviral Research (ICAR), a truly interdisciplinary meeting which attracts the interest of chemists, biologists, and clinicians.